Navigation Links
Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009
Date:1/28/2009

CHADDS FORD, Pa., Jan. 28 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals Inc. (Nasdaq: ENDP), will announce its fourth quarter and 2008 full-year financial results on February 27, 2009 and will host a conference call and webcast at 10:30 a.m. ET that day to discuss these results.

David P. Holveck, President and Chief Executive Officer, Nancy J. Wysenski, Chief Operating Officer and Blaine Davis, Vice President, Corporate Affairs will host the call.

Investors and other interested parties may call 866-543-6405 (domestic) or 617-213-8897 (international) and enter passcode 10990222. Please dial in 10 minutes prior to the scheduled start time.

A replay of the call will be available from February 27 at 1:00 p.m. ET until 12:00 a.m. ET on March 6 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and enter passcode 15067182.

A simultaneous webcast of the call may be accessed by visiting www.endo.com. In addition, a replay of the webcast will be available until 12:00 a.m. ET on March 6. The replay can be accessed by clicking on "Events" in the Investor Relations section of the website.

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.


'/>"/>
SOURCE Endo Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. XTL Biopharmaceuticals Announces Receipt of NASDAQ Notice of Delisting
2. XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
3. Indevus Pharmaceuticals Announces Release of 2008 Annual Report
4. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
5. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
6. MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
7. Axikin Pharmaceuticals Spins out of Actimis
8. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
9. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
10. Cumberland Pharmaceuticals Appoints Lee Product Director
11. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ATLANTA , Feb. 23, 2017  In Atlanta, it ... art, fashion, and culture intertwine to create an expressive and ... often reflect this energy and contribute to it. ... , Hair Fairies seeks to carry on that ... The Atlanta salon is the newest ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... 12th annual Inventors Recognition Reception at Purdue Research Park of West ... member in recognition of outstanding contributions to, and success with, commercializing discoveries from ...
(Date:2/23/2017)... SAN FRANCISCO , Feb. 23, 2017 ... company, and Beyond Type 1, a not-for-profit advocacy and ... today announced a grant from Beyond Type 1 to ... type 1 and other insulin-requiring diabetes.  ... innovative stem cell-derived cell replacement therapies with a focus ...
(Date:2/22/2017)... -- PrimeVax Immuno-Oncology, Inc. announced today its CEO, Tony ... Global Life Science Partnering Conference.  The presentation will take ... Torrey Pines Lodge, in San Diego.  ... have chosen our company, amongst numerous others, to present ... clinical researchers," said Mr. Chen. "In contrast to conferences ...
Breaking Biology Technology:
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent market research, ... a new report, Sensors for Robotics: Technologies, Markets and Forecasts ... ... Revenues ... "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine vision, force ...
(Date:1/26/2017)... -- Crossmatch, a leading provider of security and identity management ... fraud, waste and abuse in assistance operations around the ... Disaster Relief conference in Panama City ... foreign assistance organizations throughout Latin America ... largely unacknowledged problem in the foreign assistance and disaster ...
Breaking Biology News(10 mins):